These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

625 related items for PubMed ID: 22424834

  • 21. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial.
    Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J, Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR) Research Group.
    Arch Ophthalmol; 2009 Jan; 127(1):13-21. PubMed ID: 19139332
    [Abstract] [Full Text] [Related]

  • 22. Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration.
    Bashshur ZF, Schakal AR, El-Mollayess GM, Arafat S, Jaafar D, Salti HI.
    Retina; 2011 Apr; 31(4):636-44. PubMed ID: 21124254
    [Abstract] [Full Text] [Related]

  • 23. Photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy: results of a 1-year preliminary study.
    Ruamviboonsuk P, Tadarati M, Vanichvaranont S, Hanutsaha P, Pokawattana N.
    Br J Ophthalmol; 2010 Aug; 94(8):1045-51. PubMed ID: 20530656
    [Abstract] [Full Text] [Related]

  • 24. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.
    Lazic R, Gabric N.
    Ophthalmology; 2007 Jun; 114(6):1179-85. PubMed ID: 17544776
    [Abstract] [Full Text] [Related]

  • 25. Intravitreal ranibizumab and bevacizumab in combination with full-fluence verteporfin therapy and dexamethasone for exudative age-related macular degeneration.
    Forte R, Bonavolontà P, Benayoun Y, Adenis JP, Robert PY.
    Ophthalmic Res; 2011 Jun; 45(3):129-34. PubMed ID: 20847575
    [Abstract] [Full Text] [Related]

  • 26. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Ho AC, Busbee BG, Regillo CD, Wieland MR, Van Everen SA, Li Z, Rubio RG, Lai P, HARBOR Study Group.
    Ophthalmology; 2014 Nov; 121(11):2181-92. PubMed ID: 25015215
    [Abstract] [Full Text] [Related]

  • 27. Combination photodynamic therapy and intravitreal ranibizumab in neovascular age-related macular degeneration in a North Indian population: a pilot study.
    Kumar A, Gopalakrishnan K, Sinha S.
    Retina; 2008 Oct; 28(9):1296-301. PubMed ID: 18667951
    [Abstract] [Full Text] [Related]

  • 28. An observational retrospective subgroup analysis of verteporfin photodynamic therapy-naive and previously treated patients in the focus trial.
    Apte RS, Alexander SL, Henry EC, Wong P, Tuomi L.
    Retina; 2011 Jan; 31(1):56-64. PubMed ID: 20890244
    [Abstract] [Full Text] [Related]

  • 29. Comparison of Ranibizumab monotherapy versus combination of Ranibizumab with photodynamic therapy with neovascular age-related macular degeneration.
    Krebs I, Vécsei Marlovits V, Bodenstorfer J, Glittenberg C, Ansari Shahrezaei S, Ristl R, Binder S.
    Acta Ophthalmol; 2013 May; 91(3):e178-83. PubMed ID: 23241227
    [Abstract] [Full Text] [Related]

  • 30. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration.
    Augustin AJ, Schmidt-Erfurth U.
    Ophthalmology; 2006 Jan; 113(1):14-22. PubMed ID: 16360209
    [Abstract] [Full Text] [Related]

  • 31. Anti-vascular endothelial growth factor monotherapy versus combination treatment with photodynamic therapy for subfoveal choroidal neovascularization secondary to causes other than age-related macular degeneration.
    Chen L, Miller JW, Vavvas D, Kim IK.
    Retina; 2011 Nov; 31(10):2078-83. PubMed ID: 21691258
    [Abstract] [Full Text] [Related]

  • 32. Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab.
    Bressler NM, Chang TS, Varma R, Suñer I, Lee P, Dolan CM, Ward J, Ianchulev T, Fine J.
    Ophthalmology; 2013 Jan; 120(1):160-8. PubMed ID: 23009891
    [Abstract] [Full Text] [Related]

  • 33. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results.
    Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, Schneider S, Acharya NR.
    Am J Ophthalmol; 2007 Dec; 144(6):850-857. PubMed ID: 17949673
    [Abstract] [Full Text] [Related]

  • 34. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.
    Verteporfin In Photodynamic Therapy Study Group.
    Am J Ophthalmol; 2001 May; 131(5):541-60. PubMed ID: 11336929
    [Abstract] [Full Text] [Related]

  • 35. Reduced-fluence verteporfin photodynamic therapy plus ranibizumab for choroidal neovascularization in pathologic myopia.
    Rinaldi M, Semeraro F, Chiosi F, Russo A, Romano MR, Savastano MC, dell'Omo R, Costagliola C.
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):529-539. PubMed ID: 27680013
    [Abstract] [Full Text] [Related]

  • 36. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.
    Bae SH, Heo J, Kim C, Kim TW, Shin JY, Lee JY, Song SJ, Park TK, Moon SW, Chung H.
    Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858
    [Abstract] [Full Text] [Related]

  • 37. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).
    Costa RA, Jorge R, Calucci D, Melo LA, Cardillo JA, Scott IU.
    Graefes Arch Clin Exp Ophthalmol; 2007 Sep; 245(9):1273-80. PubMed ID: 17333238
    [Abstract] [Full Text] [Related]

  • 38. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.
    Azab M, Boyer DS, Bressler NM, Bressler SB, Cihelkova I, Hao Y, Immonen I, Lim JI, Menchini U, Naor J, Potter MJ, Reaves A, Rosenfeld PJ, Slakter JS, Soucek P, Strong HA, Wenkstern A, Su XY, Yang YC, Visudyne in Minimally Classic Choroidal Neovascularization Study Group.
    Arch Ophthalmol; 2005 Apr; 123(4):448-57. PubMed ID: 15824216
    [Abstract] [Full Text] [Related]

  • 39. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.
    Dhalla MS, Shah GK, Blinder KJ, Ryan EH, Mittra RA, Tewari A.
    Retina; 2006 Apr; 26(9):988-93. PubMed ID: 17151484
    [Abstract] [Full Text] [Related]

  • 40. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
    Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.